Amyotrophic Lateral Sclerosis Treatment Market Expected to Reach $1,038.94 million by 2032—Allied Market Research

According to a new report published by Allied Market Research, titled, “Amyotrophic Lateral Sclerosis Treatment Market," The amyotrophic lateral sclerosis treatment market size was valued at $662.25 million in 2022, and is estimated to reach $1,038.94 million by 2032, growing at a CAGR of 4.6% from 2023 to 2032. The amyotrophic lateral sclerosis treatment market analysis from 2022 to 2032 to identify the prevailing amyotrophic lateral sclerosis treatment market opportunity.    

Increase in prevalence of amyotrophic lateral sclerosis and rise in pipeline drugs are the major drivers of this market. For instance, according to the National Institute of Neurological Disorders and Stroke (NINDS)) on March 2023, about 5 to 10% of all ALS cases were familial (genetic). The rise in prevalence of amyotrophic lateral sclerosis led to increase in demand for ALS treatment and thus drive the growth of the market.    

Furthermore, innovative drugs for the treatment of amyotrophic lateral sclerosis, key strategies adopted by key players, and increase in awareness regarding treatment of amyotrophic lateral sclerosis fuels the market growth. For instance, in June 2022, Mitsubishi Tanabe Pharma America, Inc. a subsidiary of Mitsubishi Chemical Holdings Corporation announced  RADICAVA ORS (edaravone) that is now available in the U.S. for the treatment of amyotrophic lateral sclerosis (ALS). In addition, rise in demand for effective treatments for amyotrophic lateral sclerosis, pharmaceutical companies invest more in R&D activities to create new drugs and improve existing ones.    

Moreover, rise in awareness of early diagnosis and treatment for amyotrophic lateral sclerosis and increase in acceptability of amyotrophic lateral sclerosis treatment by medical practitioners contributes towards the growth of the amyotrophic lateral sclerosis treatment market.    

However,  limited understanding of the disease, difficulty in conducting clinical trials for ALS, due to the small number of patients with the disease and the difficulty of measuring disease progression may hinder the market growth. The regulatory process for approving new treatments for ALS may be slow and cumbersome, which may delay the availability of new therapies for patients and higher treatment cost hinder the market growth.    

ALS is a complex disease that requires specialized care from healthcare professionals, such as neurologists and respiratory therapists. The limited availability of these professionals in some areas may make it difficult for patients to access the care they need and thus may limit the growth of the amyotrophic lateral sclerosis treatment market share.      

Many people with amyotrophic lateral sclerosis had experienced delays or interruptions in their medical care due to pandemic. In addition, many healthcare resources diverted to the treatment of COVID-19, and non-urgent medical appointments and procedures postponed or canceled. Furthermore, clinical trials are essential for the development of new ALS treatments, but many clinical trials were disrupted or delayed due to the pandemic. This led to delays in the development of new treatments for ALS which negatively impacted the growth of the amyotrophic lateral sclerosis treatment market size. 

. 

The  amyotrophic lateral sclerosis treatment market is segmented on the basis of drug type, route of administration, distribution channel, and region. On the basis of drug, the market is classified into Riluzole, Edaravone, and others. The Riluzole segment exhibited the largest share in 2022 and is also expected to register highest CAGR during the amyotrophic lateral sclerosis treatment market forecast period. This is attributed to surge in high adoption of this drug by population as it slows down the progression of amyotrophic lateral sclerosis and prolong survival. In addition, Riluzole is a medication that works by reducing the release of glutamate, a neurotransmitter that may damage motor neurons in people with ALS which supports segment growth.    

On the basis of type, the amyotrophic lateral sclerosis treatment industry is categorized into sporadic ALS and familial ALS. The sporadic ALS segment exhibited the largest share in 2022. Sporadic ALS is the more common type of ALS, accounting for more than 80% of all ALS cases. Increase in cases of sporadic ALS and awareness about these diseases, along with early diagnostic tools and protocols are expected to fuel the segment growth.  However, familial ALS segment is expected to witness highest CAGR during the forecast period, owing to rise in cases of familial ALS.  

On the basis of distribution channel, the amyotrophic lateral sclerosis treatment industry is classified into hospital pharmacies, drug stores & retail pharmacies and online providers. The drug stores & retail pharmacies  segment dominated the market in 2022 and is expected to remain dominant during the forecast period, owing to rise in number of drug stores and retail pharmacies, and surge in awareness about early diagnosis and treatment of amyotrophic lateral sclerosis. However, online providers segment is expected to witness highest CAGR during the forecast period, owing to increase in trend of online shopping, availability of amyotrophic lateral sclerosis drugs such as Riluzole and Edaravone on e-commerce platforms which helps patients buy products at ease, and increased access to information offered by online providers make them an attractive option for patients with amyotrophic lateral sclerosis.   

On the basis of region, North America was the largest shareholder in the global amyotrophic lateral sclerosis treatment market in 2022, owing to early detection, availability of skilled medical professionals, presence of large patient population, ease of drug availability, and higher adoption of advanced therapeutics. In addition, the surge in the proportion of new drug launches and product approvals by the U.S. FDA is expected to drive the growth of the amyotrophic lateral sclerosis treatment market share in the region during the forecast period. For instance, in May 2022, Mitsubishi Tanabe Pharma America, Inc. announced the U.S. Food and Drug Administration (FDA) has approved RADICAVA ORS (edaravone), the oral form of Edaravone, for the treatment of amyotrophic lateral sclerosis (ALS).    

However, Asia-Pacific is anticipated to register the highest CAGR during the forecast period, owing to increase in awareness of ALS, and rise in number of people affected with amyotrophic lateral sclerosis. In addition, rise in number of skilled medical professional along with growth in availability of therapeutics that can treat ALS in emerging economies is anticipated to offer lucrative opportunities for the expansion of  amyotrophic lateral sclerosis treatment market trends. 

Key Finding of The Study 

• By drug type, the anti-platelet and anticoagulant segment held largest share in the global market in 2022.  

• By route of administration, the oral segment dominated the market in 2022. 

• By distribution channel, the drug stores & retail pharmacies segment dominated the market in 2022. 

• Region wise, North America generated the largest revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.